Surveillance of Transfusion-Transmissible Infections. Comparison of Systems in Five Developed Countries

Transfusion Medicine Reviews

Volumn 26, Issue 1, 2012, Pages 38-57

  O'Brien, Sheila F ^a   Zou, Shimian ^b   Laperche, Syria ^c   Brant, Lisa J ^d   Seed, Clive R ^e   Kleinman, Steven H ^f  

^a CANADIAN BLOOD SERVICES   (Canada)

^b AMERICAN RED CROSS   (United States)

^c INSTITUT NATIONAL DE LA TRANSFUSION SANGUINE   (France)

^d NHS BLOOD AND TRANSPLANT   (United Kingdom)

^e AUSTRALIAN RED CROSS BLOOD SERVICE   (Australia)

^f UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BABESIOSIS; BLOOD DONOR; BLOOD TRANSFUSION; CHIKUNGUNYA; DENGUE; DEVELOPED COUNTRY; DISEASE SURVEILLANCE; DISEASE TRANSMISSION; HEALTH CARE PLANNING; HEALTH PROGRAM; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN T CELL LEUKEMIA VIRUS INFECTION; INFECTION CONTROL; INFECTION PREVENTION; INFECTION RISK; INFLUENZA; MALARIA; NONHUMAN; REVIEW; SCREENING TEST; SYPHILIS; TRYPANOSOMA CRUZI; VARIANT CREUTZFELDT JAKOB DISEASE; WEST NILE FLAVIVIRUS;

AUSTRALIA; BLOOD BANKS; BLOOD DONORS; BLOOD TRANSFUSION; CANADA; COMMUNICABLE DISEASE CONTROL; DEVELOPED COUNTRIES; FRANCE; GREAT BRITAIN; HIV INFECTIONS; HUMANS; INFECTION; RISK; UNITED STATES;

EID: 82955236107     PISSN: 08877963     EISSN: 15329496     Source Type: Journal    
DOI: 10.1016/j.tmrv.2011.07.001     Document Type: Review

References (106)

1. Laperche S. Blood safety and nucleic acid testing in Europe. Euro Surveill 2005, 10:3-4.
2. Laperche S., Worms B., Pillonel J. Blood safety strategies for human T-cell lymphotropic virus in Europe. Vox Sang 2009, 96:104-110. for the European Network of Transfusion.
3. Zuck T.F., Thomson R.A., Schreiber G.B., et al. The Retrovirus Epidemiology Donor Study (REDS): Rationale and methods. Transfusion 1995, 35:944-951. for the REDS Group.
4. Krever H: Commission of inquiry on the blood system in Canada. Final Report, Canadian Government Publishing - PWGSC. Catalogue No. CP32-62/3-1997E, 1997.
5. L'Institut National de la Transfusion Sanguine (INTS). Présentation de l'INTS Available at. http://www.ints.fr/QSPresentation.aspx.
6. NHS Blood and Transplant and Health Protection Agency Centre for Infections: Safe supplies: testing the nation. NHS Blood and Transplant/ Health Protection Agency Centre for Infections Epidemiology Unit Annual Review 2009. ISSN 2044-9534 Health Protection Agency..London, 2010.
7. National Centre and HIV Epidemiology and Clinical Research. Annual Surveillance Report 2009: HIV/AIDS, viral hepatitis and sexually transmissible infections in Australia 2009: National Centre and HIV Epidemiology and Clinical Research, The University of New South Wales, Sydney, Australia; 2009.
8. Goldman M., Patterson L., Long A. Recent Canadian experience with targeted hepatitis C virus lookback. Transfusion 2006, 46:690-694.
9. Soldan K., Ramsay M., Robinson A., et al. The contribution of transfusion to HCV infection in England. Epidemiol Infect 2002, 129:587-591.
10. Soldan K., Barbara J.A., Dow B.C. Transfusion-transmitted hepatitis B virus infection in the UK: A small and moving target. Vox Sang 2002, 83:305-308.
11. Debeir J., Noel L., Aullen J.P., et al. The French haemovigilance system. Vox Sang 1999, 77:77-81.
12. Stainsby D., Jones H., Asher D., et al. Serious Hazards of Transfusion: A decade of hemovigilance in the UK. Transfus Med Rev 2006, 20:273-282.
13. Soldan K., Ramsay M., Collins M. Acute hepatitis B infection associated with blood transfusion in England and Wales, 1991-7: Review of database. BMJ 1999, 318:95.
14. Initial Australian Haemovigilance Report 2008 2008, National Blood Authority Haemovigilance Project Working Group, Commonwealth of Australia, Canberra, ACT.
15. National Blood Authority Advisory Committee Australian haemovigilance report 2010 2010, Commonwealth of Australia, Canberra, ACT.
16. Pillonel J., Laperche S. Trends in risk of transfusion-transmitted viral infections (HIV, HCV, HBV) in France between 1992 and 2003 and impact of nucleic acid testing (NAT). Euro Surveill 2005, 1:10.
17. Pillonel J., Brouard C., Laperche S., et al. Groupe de Travail Afssaps, EFS, INTS et InVS Quantitative estimate of the risk of blood donation contamination by infectious agents. Transfus Clin Biol 2009, 16:138-145.
18. Chiavetta J.A., Escobar M., Newman A., et al. Incidence and estimated rates of residual risk for HIV, hepatitis C, hepatitis B and human T-cell lymphotropic vuruses in blood donors in Canada, 1999-2000. CMAJ 2003, 169:767-773.
19. O'Brien S.F., Yi Q.L., Fan W., et al. Current incidence and estimated residual risk of transfusion-transmitted infections in donations made to Canadian Blood Services. Transfusion 2007, 47:316-325.
20. Seed C.R., Cheng A., Ismay S.L., et al. Assessing the accuracy of three viral risk models in predicting the outcome of implementing HIV and HCV NAT donor screening in Australia and the implications for future HBV NAT. Transfusion 2002, 42:1365-1372.
21. Seed C.R., Kiely P., Keller A.J. Residual risk of transfusion transmitted human immunodeficiency virus, hepatitis B virus, hepatitis C virus and human T lymphotrophic virus. Intern Med J 2005, 35:592-598.
22. Dodd R.Y., Notari E.P., Stramer S.L. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion 2002, 42:975-979.
23. Zou S., Dorsey K.A., Notari E.P., et al. Prevalence, incidence, and residual risk of human immunodeficiency virus and hepatitis C virus infections among United States blood donors since the introduction of nucleic acid testing. Transfusion 2010, 50:1495-1504.
24. Soldan K., Barbara J.A., Ramsay M.E., et al. Estimation of the risk of hepatitis B virus, hepatitis C virus and human immunodeficiency virus infectious donations entering the blood supply in England, 1993-2001. Vox Sang 2003, 84:274-286.
25. Soldan K., Davison K., Dow B.C. Estimates of the frequency of HBV, HCV, and HIV infectious donations entering the blood supply in the United Kingdom, 1996 to 2003. Euro Surveill 2005, 10:9-10.
26. Epstein J.S., Holmberg J.A. Progress in monitoring blood safety. Transfusion 2010, 50:1408-1412.
27. Kleinman S.H., Busch M.P., Korelitz J.J., et al. The incidence/window period model and its use to assess the risk of transfusion-transmitted HIV and HCV infection. Transfus Med Rev 1997, 11:155-172.
28. Schreiber G.B., Busch M.P., Kleinman S.H., et al. The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study. N Engl J Med 1996, 334:1685-1690.
29. Petersen L.R., Satten G.A., Dodd R.Y., et al. Duration of time from onset of human immunodeficiency virus type 1 infectiousness to development of detectable antibody. Transfusion 1994, 34:283-289.
30. Busch M.P., Lee L.L.L., Satten G.A., et al. Time course of detection of viral and serologic markers preceding human immunodeficiency virus type 1 seroconversion: Implications for screening of blood and tissue donors. Transfusion 1995, 35:91-97.
31. Lackritz E.M., Satten G.A., Aberle-Grasse J., et al. Estimated risk of transmission of the human immunodeficiency virus by screened blood in the United States. N Engl J Med 1995, 333:1721-1725.
32. Busch M.P., Glynn S.A., Stramer S.L., et al. A new strategy for estimating risks of transfusion-transmitted viral infections based on rates of detection of recently infected donors. Transfusion 2005, 45:254-264.
33. Korelitz J.J., Busch M.P., Kleinman S.H., et al. A method for estimating hepatitis B virus incidence rates in volunteer blood donors. National Heart, Lung and Blood Institute Retrovirus Epidemiology Donor Study. Transfusion 1997, 37:634-640.
34. Laperche S., Maniez M., Barlet V., et al. A revised method for estimating hepatitis B virus transfusion residual risk based on antibody to hepatitis B core antigen incident cases. Transfusion 2008, 48:2308-2314.
35. Zou S., Stramer S.L., Notari E.P., et al. Current incidence and residual risk of hepatitis B infection among blood donors in the United States. Transfusion 2009, 49:1609-1620.
36. Zou S., Fang C.T., Dodd R.Y. A method for estimating incidence rate of infectious diseases among first-time blood donors. Transfusion 2008, 48:1827-1832.
37. Soldan K., Barbara J.A., Heptonstall J. Incidence of seroconversion to positivity for hepatitis C antibody in repeat blood donors in England, 1993-5. BMJ 1998, 316:1413-1417.
38. Pillonel J., Barin F., Laperche S., et al. Human immunodeficiency virus type 1 incidence among blood donors in France, 1992 through 2006: Use of an immunoassay to identify recent infections. Transfusion 2008, 48:1567-1575.
39. Brant L.J., Bukasa A., Davison K.L., et al. Increase in recently acquired syphilis infections in English, Welsh and Northern Irish blood donors. Vox Sang 2007, 93:19-26.
40. O'Brien S.F., Fan W., Xi G., et al. Declining hepatitis C rates in first time blood donors: Insight from surveillance and case-control risk factor studies. Transfusion 2008, 48:902-909.
41. Zou S., Notari E.P., Fang C.T., et al. Current value of serologic test for syphilis as a surrogate marker for bloodborne viral infections among blood donors in the United States. Transfusion 2009, 49:655-661.
42. Wu Y., Zou S., Cable R., et al. Direct assessment of CMV transfusion transmitted risks post universal leukoreduction. Transfusion 2010, 50:776-786.
43. Seed C.R., Piscitelli L.M., Maine G.T., et al. Validation of an automated immunoglobulin G-only cytomegalovirus (CMV) antibody screening assay and an assessment of the risk of transfusion transmitted CMV from seronegative blood. Transfusion 2009, 49:134-145.
44. Coste J., Reesink H.W., Brown S., et al. Implementation of donor screening for infectious agents transmitted by blood by nucleic acid technology: Update to 2003. Vox Sang 2005, 88:289-303.
45. Stramer S.L., Glynn S.A., Kleinman S.H., et al. Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acid-amplification testing. N Eng J Med 2004, 251:760-768.
46. Hyland C., Seed C.R., Kiely P., et al. Follow-up of six blood donors highlights the complementary role and limitations of hepatitis C virus antibody and nucleic acid amplification tests. Vox Sang 2003, 85:1-8.
47. Laperche S., Morel P., Deschaseaux M., et al. HIV antibody screening remains indispensable for ensuring viral safety of blood components despite NAT implementation. Transfusion 2003, 43:1428-1432.
48. O'Brien S.F., Fearon M.A., Yi Q.L., et al. HBV-DNA positive, HBsAg negative blood donations intercepted by anti HBc testing: the Canadian Blood Services experience. Transfusion 2007, 47:1809-1815.
49. Brennan M., Runganga J., Barbara J.A., et al. Prevalence of antibodies to human T cell leukaemia/lymphoma virus in blood donors in north London. BMJ 1993, 307:1235-1239.
50. Davison K.L., Dow B., Barbara J.A., et al. The introduction of anti-HTLV testing of blood donations and the risk of transfusion-transmitted HTLV, UK: 2002-2006. Transfus Med 2009, 19:24-34.
51. Hewitt P.E., Howell D.R., Brant L.J., et al. HTLV lookback in NHS Blood and Transplant reveals the efficacy of leucodepletion. Vox Sang 99 Suppl.1 P-0620 2010, 320-321.
52. Polizzotto M.N., Wood E.M., Ingham H., et al. Reducing the risk of transfusion-transmissible viral infection through blood donor selection: The Australian experience 2000 through 2006. Transfusion 2008, 48:55-63.
53. O'Brien S.F., Xi G., Fan W., et al. Epidemiology of hepatitis B in Canadian blood donors. Transfusion 2008, 48:2323-2330.
54. Williams A.E., Thomson R.A., Schreiber G.B., et al. Estimates of infectious disease risk factors in US blood donors. JAMA 1997, 277:967-972.
55. O'Brien S.F., Xi G., Yi Q.L., et al. Understanding non-disclosure of deferrable risk: A study of blood donors with a history of intravenous drug use. Transfusion Med 2010, 20:15-21.
56. Orton S.L., Stramer S.L., Dodd R.Y., et al. Risk factors for HCV infection among blood donors confirmed to be positive for the presence of HCV RNA and not reactive for the presence of anti-HCV. Transfusion 2004, 44:275-281.
57. Delarocque-Astagneau E., Pillonel J., de Valk H., et al. An incident case-control study of modes of hepatitis C virus transmission: Methodological approaches in France. Ann Epidemiol 2007, 17:755-762.
58. Soldan K., Sinka K. Evaluation of the de-selection of men who have had sex with men from blood donation in England. Vox Sang 2003, 84:265-273.
59. Germain M., Remis R.S., Delage G. The risks and benefits of accepting men who have had sex with men as blood donors. Transfusion 2003, 43:25-33.
60. Leiss W., Tyshenko M., Krewski D. Men having sex with men donor deferral risk assessment: An analysis using risk management principles. Transfusion Med Rev 2008, 22:35-57.
61. Musto J.A., Seed C.R., Law M., et al. Estimating the risk of blood donation associated with HIV risk behaviours. Transfus Med 2008, 18:49-54.
62. Anderson S.A., Yang H., Gallagher L.M., et al. Quantitative estimate of risks and benefits of possible alternative blood donor deferral strategies for men who have had sex with men. Transfusion 2009, 49:1037-1042.
63. Seed C.R., Kiely P., Law M., et al. No evidence of a significantly increased risk of transfusion-transmitted human immunodeficiency virus infection in Australia subsequent to implementing a 12-month deferral for men who have had sex with men. Transfusion 2010, 50:2722-2830.
64. Zou S., Notari I.V.E.P., Musavi F., et al. Current impact of the confidential unit exclusion option. Transfusion 2004, 44:651-657.
65. O'Brien S.F., Fan W., Xi G., et al. Evaluation of the confidential unit exclusion form: The Canadian Blood Services experience. Vox Sang 2009, 98:138-144.
66. Goldman M., XI G., Yi Q.L., et al. Reassessment of deferrals for tattooing and piercing. Transfusion 2009, 49:648-654.
67. Zou S., Eder A.F., Musavi F., et al. Implementation of the Uniform Donor History Questionnaire across the American Red Cross Blood Services: Increased deferral among repeat presenters but no measurable impact on blood safety. Transfusion 2007, 47:1990-1998.
68. O'Brien S.F., Fan W., Ram S.S., et al. Face-to-face interviewing in predonation screening: Lack of effect on detected human immunodeficiency virus and hepatitis C virus infections. Transfusion 2006, 46:1380-1387.
69. Katz L.M., Cumming P.D., Wallace E.L., et al. Audiovisual touch-screen computer-assisted self-interviewing for donor health histories: Results from two years' experience with the system. Transfusion 2005, 45:171-180.
70. Goldman M., Ram S.S., Yi Q.L., et al. The Canadian donor health assessment questionnaire: Can it be improved?. Transfusion 2006, 46:2169-2175.
71. Kleinman S.H., Lelie N., Busch M.P. Infectivity of human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus and risk of transmission by transfusion. Transfusion 2009, 49:2454-2489.
72. Servant-Delmas A., Mercier M., El Ghouzzi M.H., et al. National survey of hepatitis B virus (HBV) polymorphism in asymptomatic blood donors from 1999 to 2007 in France. Transfusion 2010, 50:2607-2618.
73. Brennan C.A., Yamaguchi J., Devare S.G., et al. Expanded evaluation of blood donors in the United States for human immunodeficiency virus type 1 non-B subtypes and antiretroviral drug-resistant strains: 2005 through 2007. Transfusion 2010, 50:2707-2712.
74. Stramer S.L., Fang C.T., Foster G.A., et al. West Nile virus among blood donors in the United States, 2003 and 2004. N Engl J Med 2005, 353:451-459.
75. O'Brien S.F., Scalia V., Zuber E., et al. West Nile virus in 2006 and 2007: The Canadian Blood Services' experience. Transfusion 2010, 50:1118-1125.
76. Kleinman S.H., Williams J.D., Robertson G., et al. West Nile virus testing experience in 2007: Evaluation of different criteria for triggering individual-donation nucleic acid testing. Transfusion 2009, 49:1160-1170.
77. Leiby D.A., Read E.J., Lenes B.A., et al. Seroepidemiology of Trypanosoma cruzi, etiologic agent of Chagas' disease, in US blood donors. J Infect Dis 1997, 176:1047-1052.
78. Leiby D.A., Fucci M.H., Stumpf R.J. Trypanosoma cruzi in a low-to moderate-risk blood donor population: Seroprevalence and possible congenital transmission. Transfusion 1999, 39:310-315.
79. O'Brien S.F., Chiavetta J.A., Fan W., et al. Assessment of a travel question to identify donors with risk of Trypanosoma cruzi: Operational validity and field testing. Transfusion 2008, 48:755-761.
80. Stramer S.L., Dodd R.Y., Leiby D.A., et al. Blood donor screening for Chagas' disease-United States, 2006-2007. MMWR 2007, 56:141-143.
81. El Ghouzzi M.H., Boiret E., Wind F., et al. Testing blood donors for Chagas disease in the Paris area, France: First results after 18 months of screening. Transfusion 2010, 50:575-583.
82. Ironside J.W. Variant Creutzfeldt-Jakon disease: Risk of transmission by blood transfusion and blood therapies. Haemophilia 2006, 12:8-15.
83. Lefrere J.J., Hewitt P. From made cows to sensible blood transfusion: The risk of prion transmission by labile blood components in the UK and in France. Transfusion 2009, 49:797-812.
84. Hewitt P.E., Llewelyn C.A., Mackenzie J., et al. Creutzfeldt-Jakob disease and blood transfusion: Results of the UK transfusion medicine epidemiological review study. Vox Sang 2006, 91:221-230.
85. Chohan G., Llewelyn C., Mackenzie J., et al. Variant Creutzfeldt-Jakob disease in a transfusion recipient: Coincidence or cause?. Transfusion 2010, 50:1003-1006.
86. Garraud O., Assal A., Pelletier B., et al. Overview of revised measures to prevent malaria transmission by blood transfusion in France. Vox Sang 2008, 95:226-231.
87. Kitchen A.D., Lowe P.H., Lalloo K., et al. Evaluation of a malarial antibody assay for use in the screening of blood and tissue products for clinical use. Vox Sang 2004, 87:150-155.
88. Seed C.R., Cheng A., Davis T.M., et al. The efficacy of a malarial antibody enzyme immunoassay for establishing the reinstatement status of blood donors potentially exposed to malaria. Vox Sang 2005, 88:98-106.
89. Garraud O., Andreu G., Elghouzzi M.H., et al. Measures to prevent transfusion-associated protozoal infections in non-endemic countries. Travel Med Infect Dis 2007, 5:110-112.
90. Kitchen A.D., Barbara J.A., Hewitt P.E. Documented cases of post-transfusion malaria occurring in England: A review in relation to current and proposed donor-selection guidelines. Vox San 2005, 89:77-80.
91. Seed C.R., Kee G., Wong T., et al. Assessing the safety and efficacy of a test based, targeted screening strategy to minimise transfusion transmitted malaria. Vox Sang 2010, 93:182-192.
92. Seed C.R., Coughlin J.T., Pickworth A.M., et al. Relapsing vivax malaria despite chemoprophylaxis in two blood donors who had travelled to Papua New Guinea. Med J Aust 2010, 192:471-473.
93. Leiby D.A., Nguyen M.L., Notari E.P. Impact of donor deferrals for malaria on blood availability in the United States. Transfusion 2008, 48:2222-2228.
94. Spencer B., Steele W., Custer B., et al. Risk for malaria in United States donors deferred for travel to malaria-endemic areas. Transfusion 2009, 49:2335-2345.
95. Linnen J.M., Vinelli E., Sabino E.C., et al. Dengue viremia in blood donors from Honduras, Brazil, and Australia. Transfusion 2008, 48:1355-1362.
96. Mohammed H., Linnen J.M., Muñoz-Jordán J.L., et al. Dengue virus in blood donations, Puerto Rico, 2005. Transfusion 2008, 48:1348-1354.
97. Centers for Disease Control and Prevention Website: Available at: last date accessed 7/23/2010. http://cdc.gov/dengue/dengue_upd/index.html#us.
98. Seed C.R., Kiely P., Hyland C.A., et al. The risk of dengue transmission by blood during a 2004 outbreak in Cairns, Australia. Transfusion 2009, 49:1482-1487.
99. Johnson S.T., Cable R.G., Tonnetti L., et al. Seroprevalence of babesia microti in blood donors from Babesia-endemic areas of the northeastern United States: 2000 through 2007. Transfusion 2009, 49:2574-2582.
100. Leiby D.A., Chung A.P., Gill J.E., et al. Demonstrable parasitemia among Connecticut blood donors with antibodies to Babesia microti. Transfusion 2005, 45:1804-1810.
101. Tonnetti L., Eder A.F., Dy B., et al. Transfusion-transmitted Babesia microti identified through hemovigilance. Transfusion 2009, 49:2557-2563.
102. Gubernot D.M., Lucey C.T., Lee K.C., et al. Babesia infection through blood transfusions: Reports received by the US Food and Drug Administration, 1997-2007. CID 2009, 48:26-30.
103. Kain K.C., Jassoum S.B., Fong I.W., et al. Transfusion-transmitted babesiosis in Ontario: First reported case in Canada. CMAJ 2001, 164:1721-1723.
104. Rasonglès P., Angelini-Tibert M.F., Simon P., et al. Transfusion of platelet components prepared with photochemical pathogen inactivation treatment during a chikungunya virus epidemic in Ile de La Réunion. Transfusion 2009, 49:1083-1091.
105. Solet J.L., Camugli J.P., Laval M., et al. Transmission télématique de données épidémiologiques et surveillance de l'épidémie de chikungunya à la Réunion en 2006. Presse Med 2008, 37:593-599.
106. Brouard C., Bernillon P., Quatresous I., et al. Estimated risk of Chikungunya viremic blood donation during an epidemic on Reunion Island in the Indian Ocean, 2005 to 2007. Transfusion 2008, 48:1333-1341.